Biocryst Pharmaceuticals BCRX
NASDAQ BCRX
$8.07 -0.05 (-0.55%)
As of: Oct 2, 2026 · 1:07 PM EDT

Biocryst Pharmaceuticals (BCRX) Depreciation & Amortization (CF) (2010 - 2026)

Updated

Biocryst Pharmaceuticals (BCRX) posted Depreciation & Amortization (CF) of $513,000 for Q2 2026, up 55.9% from $329,000 a year earlier and up 11.3% from the prior quarter.

Analysis

Biocryst Pharmaceuticals (BCRX) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Depreciation & Amortization (CF) at Biocryst Pharmaceuticals was $1.7 million, up 33.0% year-over-year; for FY2025, it came in at $1.39 million, up 11.5% from FY2024.

  • Annual Depreciation & Amortization (CF) shows a five-year compound annual growth rate of 13.2% (FY2020 to FY2025).
  • In prior years, Biocryst Pharmaceuticals' Depreciation & Amortization (CF) was $1.25 million in FY2024 (-24.7%), $1.66 million in FY2023 (+15.2%), $1.44 million in FY2022 (+84.9%) and $777,000 in FY2021 (+3.9%).
  • The Q2 2026 figure stands as the highest quarterly Depreciation & Amortization (CF) since Q4 2010.
  • On a year-over-year basis, Depreciation & Amortization (CF) has increased in each of the last six quarters, with growth averaging 11.1% over the last eight quarters.
  • The strongest year-over-year quarter for Depreciation & Amortization (CF) in the past five years was Q4 2022, with growth of 131.6%; the weakest was Q4 2024, with a decline of 27.0%.
  • According to Business Quant data, Depreciation & Amortization (CF) for the three prior quarters was $461,000 (Q1 2026), $394,000 (Q4 2025) and $335,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.96 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 194.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 599.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 1.93 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.11 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 98.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 1.62 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 56.50 Mn
10 Biocryst Pharmaceuticals 2.13 Bn 1.05 Bn 214.41 Mn 513,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 513,000.00
Mar 31, 2026 461,000.00
Dec 31, 2025 394,000.00
Sep 30, 2025 335,000.00
Jun 30, 2025 329,000.00
Mar 31, 2025 331,000.00
Dec 31, 2024 309,000.00
Sep 30, 2024 311,000.00
Jun 30, 2024 320,000.00
Mar 31, 2024 306,000.00
Dec 31, 2023 423,000.00
Sep 30, 2023 420,000.00
Jun 30, 2023 407,000.00
Mar 31, 2023 405,000.00
Dec 31, 2022 396,000.00
Sep 30, 2022 389,000.00
Jun 30, 2022 335,000.00
Mar 31, 2022 317,000.00
Dec 31, 2021 171,000.00
Sep 30, 2021 229,000.00
API Access

Biocryst Pharmaceuticals Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=BCRX&period=max&api_key=YOUR_API_KEY